Bevacizumab  ||| S:0 E:12 ||| NNP
in  ||| S:12 E:15 ||| IN
combination  ||| S:15 E:27 ||| NN
with  ||| S:27 E:32 ||| IN
a  ||| S:32 E:34 ||| DT
taxane  ||| S:34 E:41 ||| NN
for  ||| S:41 E:45 ||| IN
the  ||| S:45 E:49 ||| DT
first-line  ||| S:49 E:60 ||| JJ
treatment  ||| S:60 E:70 ||| NN
of  ||| S:70 E:73 ||| IN
HER2-negative  ||| S:73 E:87 ||| CD
metastatic  ||| S:87 E:98 ||| JJ
breast  ||| S:98 E:105 ||| NN
cancer  ||| S:105 E:112 ||| NN
This  ||| S:112 E:117 ||| DT
paper  ||| S:117 E:123 ||| NN
presents  ||| S:123 E:132 ||| VBZ
a  ||| S:132 E:134 ||| DT
summary  ||| S:134 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
the  ||| S:145 E:149 ||| DT
evidence  ||| S:149 E:158 ||| NN
review  ||| S:158 E:165 ||| NN
group  ||| S:165 E:171 ||| NN
( ||| S:171 E:172 ||| -LRB-
ERG ||| S:172 E:175 ||| NNP
)  ||| S:175 E:177 ||| -RRB-
report  ||| S:177 E:184 ||| NN
into  ||| S:184 E:189 ||| IN
the  ||| S:189 E:193 ||| DT
use  ||| S:193 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
bevacizumab  ||| S:200 E:212 ||| NNS
( ||| S:212 E:213 ||| -LRB-
Avastin® ||| S:213 E:221 ||| NNP
,  ||| S:221 E:223 ||| ,
Roche ||| S:223 E:228 ||| NNP
)  ||| S:228 E:230 ||| -RRB-
in  ||| S:230 E:233 ||| IN
combination  ||| S:233 E:245 ||| NN
with  ||| S:245 E:250 ||| IN
a  ||| S:250 E:252 ||| DT
taxane  ||| S:252 E:259 ||| NN
for  ||| S:259 E:263 ||| IN
the  ||| S:263 E:267 ||| DT
treatment  ||| S:267 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
untreated  ||| S:280 E:290 ||| JJ
metastatic  ||| S:290 E:301 ||| JJ
breast  ||| S:301 E:308 ||| NN
cancer  ||| S:308 E:315 ||| NN
( ||| S:315 E:316 ||| -LRB-
mBC ||| S:316 E:319 ||| NNP
) ||| S:319 E:320 ||| -RRB-
.  ||| S:320 E:322 ||| .
The  ||| S:322 E:326 ||| DT
main  ||| S:326 E:331 ||| JJ
clinical  ||| S:331 E:340 ||| JJ
effectiveness  ||| S:340 E:354 ||| NN
data  ||| S:354 E:359 ||| NNS
were  ||| S:359 E:364 ||| VBD
derived  ||| S:364 E:372 ||| VBN
from  ||| S:372 E:377 ||| IN
a  ||| S:377 E:379 ||| DT
single ||| S:379 E:385 ||| JJ
,  ||| S:385 E:387 ||| ,
open-label  ||| S:387 E:398 ||| JJ
randomised  ||| S:398 E:409 ||| NNS
controlled  ||| S:409 E:420 ||| VBN
trial  ||| S:420 E:426 ||| NN
( ||| S:426 E:427 ||| -LRB-
RCT ||| S:427 E:430 ||| NNP
)  ||| S:430 E:432 ||| -RRB-
( ||| S:432 E:433 ||| -LRB-
E2100 ||| S:433 E:438 ||| NNP
)  ||| S:438 E:440 ||| -RRB-
that  ||| S:440 E:445 ||| WDT
evaluated  ||| S:445 E:455 ||| VBD
the  ||| S:455 E:459 ||| DT
addition  ||| S:459 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
bevacizumab  ||| S:471 E:483 ||| VBG
to  ||| S:483 E:486 ||| TO
weekly  ||| S:486 E:493 ||| JJ
( ||| S:493 E:494 ||| -LRB-
q.w. ||| S:494 E:498 ||| NNP
)  ||| S:498 E:500 ||| -RRB-
paclitaxel  ||| S:500 E:511 ||| NN
in  ||| S:511 E:514 ||| IN
patients  ||| S:514 E:523 ||| NNS
with  ||| S:523 E:528 ||| IN
human  ||| S:528 E:534 ||| JJ
epidermal  ||| S:534 E:544 ||| JJ
growth  ||| S:544 E:551 ||| NN
factor  ||| S:551 E:558 ||| NN
receptor  ||| S:558 E:567 ||| NN
2-negative  ||| S:567 E:578 ||| CD
mBC  ||| S:578 E:582 ||| NNS
who  ||| S:582 E:586 ||| WP
had  ||| S:586 E:590 ||| VBD
not  ||| S:590 E:594 ||| RB
previously  ||| S:594 E:605 ||| RB
received  ||| S:605 E:614 ||| VBD
chemotherapy  ||| S:614 E:627 ||| VBN
for  ||| S:627 E:631 ||| IN
advanced  ||| S:631 E:640 ||| JJ
disease ||| S:640 E:647 ||| NN
.  ||| S:647 E:649 ||| .
This  ||| S:649 E:654 ||| DT
trial  ||| S:654 E:660 ||| NN
reported  ||| S:660 E:669 ||| VBD
statistically  ||| S:669 E:683 ||| RB
significant  ||| S:683 E:695 ||| JJ
increases  ||| S:695 E:705 ||| NNS
in  ||| S:705 E:708 ||| IN
median  ||| S:708 E:715 ||| JJ
progression-free  ||| S:715 E:732 ||| JJ
survival  ||| S:732 E:741 ||| NN
( ||| S:741 E:742 ||| -LRB-
PFS ||| S:742 E:745 ||| NNP
)  ||| S:745 E:747 ||| -RRB-
for  ||| S:747 E:751 ||| IN
the  ||| S:751 E:755 ||| DT
addition  ||| S:755 E:764 ||| NN
of  ||| S:764 E:767 ||| IN
bevacizumab  ||| S:767 E:779 ||| NNS
( ||| S:779 E:780 ||| -LRB-
5.8-11.3  ||| S:780 E:789 ||| CD
months ||| S:789 E:795 ||| NNS
) ||| S:795 E:796 ||| -RRB-
.  ||| S:796 E:798 ||| .
Median  ||| S:798 E:805 ||| JJ
overall  ||| S:805 E:813 ||| JJ
survival  ||| S:813 E:822 ||| NN
was  ||| S:822 E:826 ||| VBD
not  ||| S:826 E:830 ||| RB
significantly  ||| S:830 E:844 ||| RB
different  ||| S:844 E:854 ||| JJ
between  ||| S:854 E:862 ||| IN
the  ||| S:862 E:866 ||| DT
two  ||| S:866 E:870 ||| CD
groups ||| S:870 E:876 ||| NNS
;  ||| S:876 E:878 ||| :
whether  ||| S:878 E:886 ||| IN
this  ||| S:886 E:891 ||| DT
is  ||| S:891 E:894 ||| VBZ
a  ||| S:894 E:896 ||| DT
true  ||| S:896 E:901 ||| JJ
null  ||| S:901 E:906 ||| JJ
finding  ||| S:906 E:914 ||| NN
or  ||| S:914 E:917 ||| CC
due  ||| S:917 E:921 ||| JJ
to  ||| S:921 E:924 ||| TO
crossover  ||| S:924 E:934 ||| VB
between  ||| S:934 E:942 ||| IN
treatment  ||| S:942 E:952 ||| NN
arms  ||| S:952 E:957 ||| NNS
cannot  ||| S:957 E:964 ||| RB
be  ||| S:964 E:967 ||| VB
established ||| S:967 E:978 ||| VBN
,  ||| S:978 E:980 ||| ,
as  ||| S:980 E:983 ||| IN
relevant  ||| S:983 E:992 ||| JJ
data  ||| S:992 E:997 ||| NNS
were  ||| S:997 E:1002 ||| VBD
not  ||| S:1002 E:1006 ||| RB
collected ||| S:1006 E:1015 ||| VBN
.  ||| S:1015 E:1017 ||| .
The  ||| S:1017 E:1021 ||| DT
manufacturer  ||| S:1021 E:1034 ||| NN
reported  ||| S:1034 E:1043 ||| VBD
that  ||| S:1043 E:1048 ||| IN
the  ||| S:1048 E:1052 ||| DT
addition  ||| S:1052 E:1061 ||| NN
of  ||| S:1061 E:1064 ||| IN
bevacizumab  ||| S:1064 E:1076 ||| VBG
to  ||| S:1076 E:1079 ||| TO
paclitaxel  ||| S:1079 E:1090 ||| CD
q.w.  ||| S:1090 E:1095 ||| CD
therapy  ||| S:1095 E:1103 ||| NN
was  ||| S:1103 E:1107 ||| VBD
associated  ||| S:1107 E:1118 ||| VBN
with  ||| S:1118 E:1123 ||| IN
a  ||| S:1123 E:1125 ||| DT
significant  ||| S:1125 E:1137 ||| JJ
improvement  ||| S:1137 E:1149 ||| NN
in  ||| S:1149 E:1152 ||| IN
quality  ||| S:1152 E:1160 ||| NN
of  ||| S:1160 E:1163 ||| IN
life ||| S:1163 E:1167 ||| NN
,  ||| S:1167 E:1169 ||| ,
as  ||| S:1169 E:1172 ||| RB
measured  ||| S:1172 E:1181 ||| VBN
by  ||| S:1181 E:1184 ||| IN
FACT-B  ||| S:1184 E:1191 ||| NNP
( ||| S:1191 E:1192 ||| -LRB-
functional  ||| S:1192 E:1203 ||| JJ
assessment  ||| S:1203 E:1214 ||| NN
of  ||| S:1214 E:1217 ||| IN
cancer  ||| S:1217 E:1224 ||| NN
therapy  ||| S:1224 E:1232 ||| NN
for  ||| S:1232 E:1236 ||| IN
breast  ||| S:1236 E:1243 ||| JJ
cancer ||| S:1243 E:1249 ||| NN
)  ||| S:1249 E:1251 ||| -RRB-
scores ||| S:1251 E:1257 ||| NNS
.  ||| S:1257 E:1259 ||| .
However ||| S:1259 E:1266 ||| RB
,  ||| S:1266 E:1268 ||| ,
the  ||| S:1268 E:1272 ||| DT
ERG  ||| S:1272 E:1276 ||| NNP
noted  ||| S:1276 E:1282 ||| VBD
that  ||| S:1282 E:1287 ||| IN
these  ||| S:1287 E:1293 ||| DT
results  ||| S:1293 E:1301 ||| NNS
were  ||| S:1301 E:1306 ||| VBD
based  ||| S:1306 E:1312 ||| VBN
on  ||| S:1312 E:1315 ||| IN
extreme  ||| S:1315 E:1323 ||| JJ
imputed  ||| S:1323 E:1331 ||| JJ
values ||| S:1331 E:1337 ||| NNS
,  ||| S:1337 E:1339 ||| ,
the  ||| S:1339 E:1343 ||| DT
removal  ||| S:1343 E:1351 ||| NN
of  ||| S:1351 E:1354 ||| IN
which  ||| S:1354 E:1360 ||| WDT
led  ||| S:1360 E:1364 ||| VBD
to  ||| S:1364 E:1367 ||| TO
non-significant  ||| S:1367 E:1383 ||| JJ
differences  ||| S:1383 E:1395 ||| NNS
in  ||| S:1395 E:1398 ||| IN
quality  ||| S:1398 E:1406 ||| NN
of  ||| S:1406 E:1409 ||| IN
life ||| S:1409 E:1413 ||| NN
.  ||| S:1413 E:1415 ||| .
The  ||| S:1415 E:1419 ||| DT
manufacturer  ||| S:1419 E:1432 ||| NN
conducted  ||| S:1432 E:1442 ||| VBD
an  ||| S:1442 E:1445 ||| DT
indirect  ||| S:1445 E:1454 ||| JJ
comparison ||| S:1454 E:1464 ||| NN
.  ||| S:1464 E:1466 ||| .
However ||| S:1466 E:1473 ||| RB
,  ||| S:1473 E:1475 ||| ,
owing  ||| S:1475 E:1481 ||| VBG
to  ||| S:1481 E:1484 ||| TO
methodological  ||| S:1484 E:1499 ||| VB
limitations  ||| S:1499 E:1511 ||| NNS
and  ||| S:1511 E:1515 ||| CC
concerns  ||| S:1515 E:1524 ||| NNS
about  ||| S:1524 E:1530 ||| IN
the  ||| S:1530 E:1534 ||| DT
validity  ||| S:1534 E:1543 ||| NN
and  ||| S:1543 E:1547 ||| CC
exchangeability  ||| S:1547 E:1563 ||| NN
of  ||| S:1563 E:1566 ||| IN
the  ||| S:1566 E:1570 ||| DT
included  ||| S:1570 E:1579 ||| JJ
trials ||| S:1579 E:1585 ||| NNS
,  ||| S:1585 E:1587 ||| ,
the  ||| S:1587 E:1591 ||| DT
ERG  ||| S:1591 E:1595 ||| NNP
did  ||| S:1595 E:1599 ||| VBD
not  ||| S:1599 E:1603 ||| RB
consider  ||| S:1603 E:1612 ||| VB
the  ||| S:1612 E:1616 ||| DT
findings  ||| S:1616 E:1625 ||| NNS
to  ||| S:1625 E:1628 ||| TO
be  ||| S:1628 E:1631 ||| VB
reliable ||| S:1631 E:1639 ||| JJ
.  ||| S:1639 E:1641 ||| .
One  ||| S:1641 E:1645 ||| CD
additional  ||| S:1645 E:1656 ||| JJ
relevant  ||| S:1656 E:1665 ||| JJ
RCT  ||| S:1665 E:1669 ||| NNP
[ ||| S:1669 E:1670 ||| -LRB-
AVADO  ||| S:1670 E:1676 ||| NNP
( ||| S:1676 E:1677 ||| -LRB-
Avastin  ||| S:1677 E:1685 ||| NNP
and  ||| S:1685 E:1689 ||| CC
Docetaxel ||| S:1689 E:1698 ||| NNP
) ||| S:1698 E:1699 ||| -RRB-
;  ||| S:1699 E:1701 ||| :
BO17708 ||| S:1701 E:1708 ||| CD
]  ||| S:1708 E:1710 ||| -RRB-
evaluating  ||| S:1710 E:1721 ||| VBG
the  ||| S:1721 E:1725 ||| DT
addition  ||| S:1725 E:1734 ||| NN
of  ||| S:1734 E:1737 ||| IN
bevacizumab  ||| S:1737 E:1749 ||| VBG
to  ||| S:1749 E:1752 ||| TO
docetaxel  ||| S:1752 E:1762 ||| NNS
was  ||| S:1762 E:1766 ||| VBD
excluded  ||| S:1766 E:1775 ||| VBN
from  ||| S:1775 E:1780 ||| IN
the  ||| S:1780 E:1784 ||| DT
manufacturer ||| S:1784 E:1796 ||| NN
's  ||| S:1796 E:1799 ||| POS
submission ||| S:1799 E:1809 ||| NN
.  ||| S:1809 E:1811 ||| .
This  ||| S:1811 E:1816 ||| DT
was  ||| S:1816 E:1820 ||| VBD
summarised  ||| S:1820 E:1831 ||| VBN
by  ||| S:1831 E:1834 ||| IN
the  ||| S:1834 E:1838 ||| DT
ERG ||| S:1838 E:1841 ||| NNP
.  ||| S:1841 E:1843 ||| .
In  ||| S:1843 E:1846 ||| IN
terms  ||| S:1846 E:1852 ||| NNS
of  ||| S:1852 E:1855 ||| IN
response  ||| S:1855 E:1864 ||| NN
rate  ||| S:1864 E:1869 ||| NN
and  ||| S:1869 E:1873 ||| CC
PFS ||| S:1873 E:1876 ||| NNP
,  ||| S:1876 E:1878 ||| ,
AVADO  ||| S:1878 E:1884 ||| NNP
reported  ||| S:1884 E:1893 ||| VBD
a  ||| S:1893 E:1895 ||| DT
markedly  ||| S:1895 E:1904 ||| RB
smaller  ||| S:1904 E:1912 ||| JJR
benefit  ||| S:1912 E:1920 ||| NN
of  ||| S:1920 E:1923 ||| IN
adding  ||| S:1923 E:1930 ||| VBG
bevacizumab  ||| S:1930 E:1942 ||| NN
to  ||| S:1942 E:1945 ||| TO
docetaxel  ||| S:1945 E:1955 ||| VB
than  ||| S:1955 E:1960 ||| IN
that  ||| S:1960 E:1965 ||| WDT
reported  ||| S:1965 E:1974 ||| VBD
for  ||| S:1974 E:1978 ||| IN
adding  ||| S:1978 E:1985 ||| VBG
bevacizumab  ||| S:1985 E:1997 ||| NN
to  ||| S:1997 E:2000 ||| TO
q.w.  ||| S:2000 E:2005 ||| CD
paclitaxel  ||| S:2005 E:2016 ||| NN
in  ||| S:2016 E:2019 ||| IN
E2100 ||| S:2019 E:2024 ||| CD
.  ||| S:2024 E:2026 ||| .
AVADO  ||| S:2026 E:2032 ||| NNP
also  ||| S:2032 E:2037 ||| RB
reported  ||| S:2037 E:2046 ||| VBD
no  ||| S:2046 E:2049 ||| DT
statistically  ||| S:2049 E:2063 ||| JJ
significant  ||| S:2063 E:2075 ||| JJ
effect  ||| S:2075 E:2082 ||| NN
of  ||| S:2082 E:2085 ||| IN
combination  ||| S:2085 E:2097 ||| NN
therapy  ||| S:2097 E:2105 ||| NN
versus  ||| S:2105 E:2112 ||| IN
docetaxel  ||| S:2112 E:2122 ||| NN
in  ||| S:2122 E:2125 ||| IN
terms  ||| S:2125 E:2131 ||| NNS
of  ||| S:2131 E:2134 ||| IN
overall  ||| S:2134 E:2142 ||| JJ
survival ||| S:2142 E:2150 ||| NN
.  ||| S:2150 E:2152 ||| .
The  ||| S:2152 E:2156 ||| DT
manufacturer  ||| S:2156 E:2169 ||| NN
developed  ||| S:2169 E:2179 ||| VBD
a  ||| S:2179 E:2181 ||| DT
de  ||| S:2181 E:2184 ||| FW
novo  ||| S:2184 E:2189 ||| FW
economic  ||| S:2189 E:2198 ||| JJ
model  ||| S:2198 E:2204 ||| NN
that  ||| S:2204 E:2209 ||| IN
considered  ||| S:2209 E:2220 ||| VBN
patients  ||| S:2220 E:2229 ||| NNS
with  ||| S:2229 E:2234 ||| IN
the  ||| S:2234 E:2238 ||| DT
same  ||| S:2238 E:2243 ||| JJ
baseline  ||| S:2243 E:2252 ||| NN
characteristics  ||| S:2252 E:2268 ||| NNS
as  ||| S:2268 E:2271 ||| IN
women  ||| S:2271 E:2277 ||| NNS
in  ||| S:2277 E:2280 ||| IN
the  ||| S:2280 E:2284 ||| DT
E2100  ||| S:2284 E:2290 ||| JJ
trial ||| S:2290 E:2295 ||| NN
.  ||| S:2295 E:2297 ||| .
The  ||| S:2297 E:2301 ||| DT
model  ||| S:2301 E:2307 ||| NN
assessed  ||| S:2307 E:2316 ||| VBD
BEV  ||| S:2316 E:2320 ||| NNP
+  ||| S:2320 E:2322 ||| NNP
PAC  ||| S:2322 E:2326 ||| NNP
-  ||| S:2326 E:2328 ||| :
bevacizumab  ||| S:2328 E:2340 ||| CD
10  ||| S:2340 E:2343 ||| CD
mg ||| S:2343 E:2345 ||| CD
/ ||| S:2345 E:2346 ||| CD
kg  ||| S:2346 E:2349 ||| CD
every  ||| S:2349 E:2355 ||| DT
2  ||| S:2355 E:2357 ||| CD
weeks  ||| S:2357 E:2363 ||| NNS
in  ||| S:2363 E:2366 ||| IN
combination  ||| S:2366 E:2378 ||| NN
with  ||| S:2378 E:2383 ||| IN
paclitaxel  ||| S:2383 E:2394 ||| CD
90  ||| S:2394 E:2397 ||| CD
mg ||| S:2397 E:2399 ||| CD
/ ||| S:2399 E:2400 ||| CD
m2  ||| S:2400 E:2403 ||| CD
weekly  ||| S:2403 E:2410 ||| JJ
for  ||| S:2410 E:2414 ||| IN
3  ||| S:2414 E:2416 ||| CD
weeks  ||| S:2416 E:2422 ||| NNS
followed  ||| S:2422 E:2431 ||| VBN
by  ||| S:2431 E:2434 ||| IN
1  ||| S:2434 E:2436 ||| CD
week  ||| S:2436 E:2441 ||| NN
of  ||| S:2441 E:2444 ||| IN
rest ||| S:2444 E:2448 ||| NN
;  ||| S:2448 E:2450 ||| :
PAC  ||| S:2450 E:2454 ||| NNP
q.w.  ||| S:2454 E:2459 ||| NNP
-  ||| S:2459 E:2461 ||| :
paclitaxel  ||| S:2461 E:2472 ||| CD
( ||| S:2472 E:2473 ||| -LRB-
monotherapy ||| S:2473 E:2484 ||| LS
)  ||| S:2484 E:2486 ||| -RRB-
90  ||| S:2486 E:2489 ||| CD
mg ||| S:2489 E:2491 ||| CD
/ ||| S:2491 E:2492 ||| CD
m2  ||| S:2492 E:2495 ||| CD
weekly  ||| S:2495 E:2502 ||| JJ
for  ||| S:2502 E:2506 ||| IN
3  ||| S:2506 E:2508 ||| CD
weeks  ||| S:2508 E:2514 ||| NNS
followed  ||| S:2514 E:2523 ||| VBN
by  ||| S:2523 E:2526 ||| IN
1  ||| S:2526 E:2528 ||| CD
week  ||| S:2528 E:2533 ||| NN
of  ||| S:2533 E:2536 ||| IN
rest ||| S:2536 E:2540 ||| NN
;  ||| S:2540 E:2542 ||| :
DOC  ||| S:2542 E:2546 ||| NNP
-  ||| S:2546 E:2548 ||| :
docetaxel  ||| S:2548 E:2558 ||| CD
( ||| S:2558 E:2559 ||| -LRB-
monotherapy ||| S:2559 E:2570 ||| LS
)  ||| S:2570 E:2572 ||| -RRB-
75  ||| S:2572 E:2575 ||| CD
mg ||| S:2575 E:2577 ||| CD
/ ||| S:2577 E:2578 ||| CD
m2  ||| S:2578 E:2581 ||| CD
on  ||| S:2581 E:2584 ||| IN
day  ||| S:2584 E:2588 ||| NN
1  ||| S:2588 E:2590 ||| CD
every  ||| S:2590 E:2596 ||| DT
21  ||| S:2596 E:2599 ||| CD
days  ||| S:2599 E:2604 ||| NNS
( ||| S:2604 E:2605 ||| -LRB-
considered  ||| S:2605 E:2616 ||| VBN
current  ||| S:2616 E:2624 ||| JJ
UK  ||| S:2624 E:2627 ||| NNP
NHS  ||| S:2627 E:2631 ||| NNP
clinical  ||| S:2631 E:2640 ||| JJ
practice  ||| S:2640 E:2649 ||| NN
in  ||| S:2649 E:2652 ||| IN
the  ||| S:2652 E:2656 ||| DT
submission ||| S:2656 E:2666 ||| NN
) ||| S:2666 E:2667 ||| -RRB-
;  ||| S:2667 E:2669 ||| :
and  ||| S:2669 E:2673 ||| CC
GEM  ||| S:2673 E:2677 ||| NNP
+  ||| S:2677 E:2679 ||| NNP
PAC  ||| S:2679 E:2683 ||| NNP
-  ||| S:2683 E:2685 ||| :
gemcitabine  ||| S:2685 E:2697 ||| CD
1250  ||| S:2697 E:2702 ||| CD
mg ||| S:2702 E:2704 ||| CD
/ ||| S:2704 E:2705 ||| CD
m2  ||| S:2705 E:2708 ||| CD
on  ||| S:2708 E:2711 ||| IN
days  ||| S:2711 E:2716 ||| NNS
1  ||| S:2716 E:2718 ||| CD
and  ||| S:2718 E:2722 ||| CC
8  ||| S:2722 E:2724 ||| CD
plus  ||| S:2724 E:2729 ||| CC
paclitaxel  ||| S:2729 E:2740 ||| CD
175  ||| S:2740 E:2744 ||| CD
mg ||| S:2744 E:2746 ||| CD
/ ||| S:2746 E:2747 ||| CD
m2  ||| S:2747 E:2750 ||| CD
on  ||| S:2750 E:2753 ||| IN
day  ||| S:2753 E:2757 ||| NN
1  ||| S:2757 E:2759 ||| CD
every  ||| S:2759 E:2765 ||| DT
21  ||| S:2765 E:2768 ||| CD
days ||| S:2768 E:2772 ||| NNS
.  ||| S:2772 E:2774 ||| .
Pairwise  ||| S:2774 E:2783 ||| JJ
comparisons  ||| S:2783 E:2795 ||| NNS
were  ||| S:2795 E:2800 ||| VBD
made  ||| S:2800 E:2805 ||| VBN
between  ||| S:2805 E:2813 ||| IN
BEV  ||| S:2813 E:2817 ||| NNP
+  ||| S:2817 E:2819 ||| NNP
PAC  ||| S:2819 E:2823 ||| NNP
and  ||| S:2823 E:2827 ||| CC
PAC  ||| S:2827 E:2831 ||| NNP
( ||| S:2831 E:2832 ||| -LRB-
using  ||| S:2832 E:2838 ||| VBG
the  ||| S:2838 E:2842 ||| DT
E2100  ||| S:2842 E:2848 ||| JJ
trial ||| S:2848 E:2853 ||| NN
) ||| S:2853 E:2854 ||| -RRB-
,  ||| S:2854 E:2856 ||| ,
BEV  ||| S:2856 E:2860 ||| NNP
+  ||| S:2860 E:2862 ||| NNP
PAC  ||| S:2862 E:2866 ||| NNP
and  ||| S:2866 E:2870 ||| CC
DOC ||| S:2870 E:2873 ||| NNP
,  ||| S:2873 E:2875 ||| ,
and  ||| S:2875 E:2879 ||| CC
BEV  ||| S:2879 E:2883 ||| NNP
+  ||| S:2883 E:2885 ||| NNP
PAC  ||| S:2885 E:2889 ||| NNP
and  ||| S:2889 E:2893 ||| CC
GEM  ||| S:2893 E:2897 ||| NNP
+  ||| S:2897 E:2899 ||| NNP
PAC ||| S:2899 E:2902 ||| NNP
.  ||| S:2902 E:2904 ||| .
Based  ||| S:2904 E:2910 ||| VBN
on  ||| S:2910 E:2913 ||| IN
NHS  ||| S:2913 E:2917 ||| NNP
list  ||| S:2917 E:2922 ||| NN
prices ||| S:2922 E:2928 ||| NNS
,  ||| S:2928 E:2930 ||| ,
the  ||| S:2930 E:2934 ||| DT
manufacturer ||| S:2934 E:2946 ||| NN
's  ||| S:2946 E:2949 ||| POS
model  ||| S:2949 E:2955 ||| NN
estimated  ||| S:2955 E:2965 ||| VBD
incremental  ||| S:2965 E:2977 ||| JJ
cost-effectiveness  ||| S:2977 E:2996 ||| JJ
ratios  ||| S:2996 E:3003 ||| NNS
( ||| S:3003 E:3004 ||| -LRB-
ICERs ||| S:3004 E:3009 ||| NNP
)  ||| S:3009 E:3011 ||| -RRB-
for  ||| S:3011 E:3015 ||| IN
BEV  ||| S:3015 E:3019 ||| NNP
+  ||| S:3019 E:3021 ||| NNP
PAC  ||| S:3021 E:3025 ||| NNP
of  ||| S:3025 E:3028 ||| IN
£  ||| S:3028 E:3030 ||| CD
117,803 ||| S:3030 E:3037 ||| CD
,  ||| S:3037 E:3039 ||| ,
£  ||| S:3039 E:3041 ||| NNP
115,059  ||| S:3041 E:3049 ||| NNP
and  ||| S:3049 E:3053 ||| CC
£  ||| S:3053 E:3055 ||| CD
105,777  ||| S:3055 E:3063 ||| CD
per  ||| S:3063 E:3067 ||| IN
QALY  ||| S:3067 E:3072 ||| NNP
gained ||| S:3072 E:3078 ||| VBD
,  ||| S:3078 E:3080 ||| ,
relative  ||| S:3080 E:3089 ||| JJ
to  ||| S:3089 E:3092 ||| TO
PAC ||| S:3092 E:3095 ||| NNP
,  ||| S:3095 E:3097 ||| ,
DOC  ||| S:3097 E:3101 ||| NNP
and  ||| S:3101 E:3105 ||| CC
GEM  ||| S:3105 E:3109 ||| NNP
+  ||| S:3109 E:3111 ||| NNP
PAC  ||| S:3111 E:3115 ||| NNP
regimens ||| S:3115 E:3123 ||| NN
,  ||| S:3123 E:3125 ||| ,
respectively ||| S:3125 E:3137 ||| RB
.  ||| S:3137 E:3139 ||| .
If  ||| S:3139 E:3142 ||| IN
the  ||| S:3142 E:3146 ||| DT
NHS  ||| S:3146 E:3150 ||| NNP
Purchasing  ||| S:3150 E:3161 ||| NNP
and  ||| S:3161 E:3165 ||| CC
Supply  ||| S:3165 E:3172 ||| NNP
Agency  ||| S:3172 E:3179 ||| NNP
prices  ||| S:3179 E:3186 ||| NNS
for  ||| S:3186 E:3190 ||| IN
PAC  ||| S:3190 E:3194 ||| NNP
with  ||| S:3194 E:3199 ||| IN
a  ||| S:3199 E:3201 ||| DT
10-g  ||| S:3201 E:3206 ||| JJ
cap  ||| S:3206 E:3210 ||| NN
on  ||| S:3210 E:3213 ||| IN
the  ||| S:3213 E:3217 ||| DT
cost  ||| S:3217 E:3222 ||| NN
per  ||| S:3222 E:3226 ||| IN
patient  ||| S:3226 E:3234 ||| NN
of  ||| S:3234 E:3237 ||| IN
BEV  ||| S:3237 E:3241 ||| NNP
were  ||| S:3241 E:3246 ||| VBD
used  ||| S:3246 E:3251 ||| VBN
instead ||| S:3251 E:3258 ||| RB
,  ||| S:3258 E:3260 ||| ,
the  ||| S:3260 E:3264 ||| DT
ICERs  ||| S:3264 E:3270 ||| JJ
for  ||| S:3270 E:3274 ||| IN
BEV  ||| S:3274 E:3278 ||| NNP
+  ||| S:3278 E:3280 ||| NNP
PAC  ||| S:3280 E:3284 ||| NNP
were  ||| S:3284 E:3289 ||| VBD
estimated  ||| S:3289 E:3299 ||| VBN
at  ||| S:3299 E:3302 ||| IN
£  ||| S:3302 E:3304 ||| CD
77,314 ||| S:3304 E:3310 ||| CD
,  ||| S:3310 E:3312 ||| ,
£  ||| S:3312 E:3314 ||| NNP
57,753  ||| S:3314 E:3321 ||| NNP
and  ||| S:3321 E:3325 ||| CC
£  ||| S:3325 E:3327 ||| CD
60,101  ||| S:3327 E:3334 ||| CD
per  ||| S:3334 E:3338 ||| IN
QALY ||| S:3338 E:3342 ||| NNP
,  ||| S:3342 E:3344 ||| ,
respectively ||| S:3344 E:3356 ||| RB
.  ||| S:3356 E:3358 ||| .
The  ||| S:3358 E:3362 ||| DT
submission  ||| S:3362 E:3373 ||| NN
suggested  ||| S:3373 E:3383 ||| VBD
that  ||| S:3383 E:3388 ||| IN
the  ||| S:3388 E:3392 ||| DT
regimen  ||| S:3392 E:3400 ||| NN
of  ||| S:3400 E:3403 ||| IN
BEV  ||| S:3403 E:3407 ||| NNP
+  ||| S:3407 E:3409 ||| NNP
DOC  ||| S:3409 E:3413 ||| NNP
is  ||| S:3413 E:3416 ||| VBZ
not  ||| S:3416 E:3420 ||| RB
cost-effective  ||| S:3420 E:3435 ||| JJ
because  ||| S:3435 E:3443 ||| IN
it  ||| S:3443 E:3446 ||| PRP
is  ||| S:3446 E:3449 ||| VBZ
considered  ||| S:3449 E:3460 ||| VBN
less  ||| S:3460 E:3465 ||| RBR
effective  ||| S:3465 E:3475 ||| JJ
and  ||| S:3475 E:3479 ||| CC
more  ||| S:3479 E:3484 ||| RBR
costly  ||| S:3484 E:3491 ||| JJ
than  ||| S:3491 E:3496 ||| IN
BEV  ||| S:3496 E:3500 ||| NNP
+  ||| S:3500 E:3502 ||| NNP
PAC ||| S:3502 E:3505 ||| NNP
.  ||| S:3505 E:3507 ||| .
Analysis  ||| S:3507 E:3516 ||| NN
by  ||| S:3516 E:3519 ||| IN
the  ||| S:3519 E:3523 ||| DT
ERG  ||| S:3523 E:3527 ||| NNP
suggested  ||| S:3527 E:3537 ||| VBD
that  ||| S:3537 E:3542 ||| DT
alternative  ||| S:3542 E:3554 ||| JJ
assumptions  ||| S:3554 E:3566 ||| NNS
can  ||| S:3566 E:3570 ||| MD
increase  ||| S:3570 E:3579 ||| VB
the  ||| S:3579 E:3583 ||| DT
ICERs  ||| S:3583 E:3589 ||| JJ
further  ||| S:3589 E:3597 ||| JJ
and ||| S:3597 E:3600 ||| CC
,  ||| S:3600 E:3602 ||| ,
based  ||| S:3602 E:3608 ||| VBN
on  ||| S:3608 E:3611 ||| IN
current  ||| S:3611 E:3619 ||| JJ
prices ||| S:3619 E:3625 ||| NNS
,  ||| S:3625 E:3627 ||| ,
no  ||| S:3627 E:3630 ||| DT
plausible  ||| S:3630 E:3640 ||| JJ
changes  ||| S:3640 E:3648 ||| NNS
to  ||| S:3648 E:3651 ||| TO
the  ||| S:3651 E:3655 ||| DT
model  ||| S:3655 E:3661 ||| NN
assumptions  ||| S:3661 E:3673 ||| NNS
will  ||| S:3673 E:3678 ||| MD
bring  ||| S:3678 E:3684 ||| VB
the  ||| S:3684 E:3688 ||| DT
ICERs  ||| S:3688 E:3694 ||| JJ
for  ||| S:3694 E:3698 ||| IN
BEV  ||| S:3698 E:3702 ||| NNP
+  ||| S:3702 E:3704 ||| NNP
PAC  ||| S:3704 E:3708 ||| NNP
lower ||| S:3708 E:3713 ||| RBR
.  ||| S:3713 E:3715 ||| .
